Britain’s medicines regulator gave the green light Thursday to a new Alzheimer’s drug which has shown to slow progression of the disease, making it Britain’s first such licensed treatment. Lecanemab, which is designed to slow down cognitive decline in people with the neurological condition, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA). […]
The post UK regulator approves new Alzheimer’s drug appeared first on Insider Paper.